1 / 35

IN THE NAME OF GOD

IN THE NAME OF GOD. Hypertension. Mohammad Garakyaraghi,MD Cardiologist Associate Professor. Hypertension. Hypertension is the most common condition in primary care. 1 in 3 patients have hypertension according to NHLBI Risk factor for MI, CVA, ARF, death. New Guidelines for Hypertension.

niveditha
Télécharger la présentation

IN THE NAME OF GOD

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. IN THE NAME OF GOD

  2. Hypertension Mohammad Garakyaraghi,MD Cardiologist Associate Professor

  3. Hypertension • Hypertension is the most common condition in primary care. • 1 in 3 patients have hypertension according to NHLBI • Risk factor for MI, CVA, ARF, death

  4. New Guidelines for Hypertension • National Institute for Health and Clinical Excellence (NICE), 2011 • Kidney Disease: Improving Global Outcome (KDIGO), 2012 • European Society of Hypertension/European Society of Cardiology, (ESH/ESC), 2013 • American Diabetes Association (ADA), 2014 • American Society of Hypertension and the International Society of Hypertension (ASH/ISH), 2014 • Eighth Joint National Committee (JNC8), 2013

  5. JNC 8: Hypertension ManagementEvidence Review • Limited to RCT’s • Hypertensive adults > 18 years old • Sample size > 100 • Follow-up > 1 year • Reported effect of treatment on important health outcomes (mortality, MI, HF, CVA, ESRD) • January 1966 to December 2009 • Separate criteria used of RCT’s published after December 2009

  6. JNC 8: Hypertension ManagementEvidence Review • RCT’s December 2009 – August 2013 • Major study in hypertension • ACCORD, NEJM 2010 • > 2,000 participants • Multicentered • Met all other inclusion/exclusion criteria

  7. JNC8: Methods • Excluded sample size < 100 and f/up period < 1 year • Only included randomized, controlled trials rated as good or fair • Only included studies reporting effects of interventions on: • MI • Stroke • ESRD, doubling of Scr, or halving of GFR • Heart failure (HF) or hospitalization for HF • Coronary revascularization or other revascularization • Mortality (Overall mortality, CVD-related mortality, CKD-related mortality)

  8. JNC 8: Graded Recommendations A – Strong evidence B – Moderate evidence C – Weak evidence D – Against E – Expert Opinion N – No recommendation

  9. JNC8: Strength of Recommendation

  10. JNC8: Key Questions • In adults with HTN, does initiating antihypertensive pharmacologic therapy at specific BP thresholds improve health outcomes? • In adults with HTN, does treatment with antihypertensive pharmacologic therapy to a specified BP goal lead to improvements in health outcomes? • In adults with HTN, do various antihypertensive drugs or drug classes differ in comparative benefits and harms on specific health outcomes?

  11. JNC 8: Drug TreatmentThresholds and Goals • Age > 60 yo • Systolic: • Threshold > 150 mmHg • Goal < 150 mmHg • LOE: Grade A • Diastolic: • Threshold > 90 mmHg • Goal < 90 mmHg • LOE: Grade A

  12. JNC 8: Drug TreatmentThresholds and Goals • Age < 60 yo • Systolic: • Threshold > 140 mmHg • Goal < 140 mmHg • LOE: Grade E • Diastolic: • Threshold > 90 mmHg • Goal < 90 mmHg • LOE: Grade A for ages 40-59; Grade E for ages 18-39

  13. JNC 8: Drug TreatmentThresholds and Goals • Age > 18 yo with CKD or DM • JNC 7: < 130/80 (MDRD NEJM 1994) • Systolic: • Threshold > 140 mmHg • Goal < 140 mmHg • LOE: Grade E • Diastolic: • Threshold > 90 mmHg • Goal < 90 mmHg • LOE: Grade E

  14. JNC 8: Initial Drug Choice • Nonblack, including DM • Thiazide diuretic, CCB, ACEI, ARB • LOE: Grade B • Black, including DM • Thiazide diuretic, CCB • LOE: Grade B (Grade C for diabetics)

  15. JNC 8: Initial Drug Choice • Age > 18 yo with CKD and HTN (regardless of race or diabetes) • Initial (or add-on) therapy should include an ACEI or ARB to improve kidney outcomes • LOE: Grade B • Blacks w/ or w/o proteinuria • ACEI or ARB as initial therapy (LOE: Grade E) • No evidence for RAS-blockers > 75 yo • Diuretic is an option for initial therapy

  16. JNC8: Treatment Strategies (Grade E) • If goal BP not met after 1 month of treatment: • Increase dose of initial drug, or • Add a second drug (Thiazide, CCB, ACEi, or ARB) • If goal BP not met with 2 medications: • Add and titrate a third medication (Thiazide, CCB, ACEi, or ARB) • Do not use ACE and ARB together • Other classes may be used in the following scenarios: • Goal BP not met with 3 medications • Contraindication to thiazide, ACE/ARB, or CCB

  17. Strategies to Dose Antihypertensive Drugs • Titrate to max dose, then add a second drug • Add a second drug before achieving max dose of the initial drug • Start with 2 drugs at the same time • If SBP ≥ 160mmHg and/or DBP ≥ 100 mmHg • If SBP ≥ 20mmHg above goal and/or DBP ≥ 10mmHg above goal ***Consider scheduling follow-up with the Enhanced Care Clinic for titration of BP Meds

  18. Comparison of RecentGuideline Statements

  19. Goal BP **KDIGO: <140/90 w/o albuminuria <130/80 if >30 mg/24hr *ADA: < 140/80 or lower

  20. Comparison of JNC Guidelines JNC7 JNC8 Systematic review Randomized, controlled trials (RCT) only Graded recommendations Recommendations: No specific lifestyle recommendations Initial therapy for HTN Racial, CKD, and diabetic subgroups addressed Addressed three key questions • Nonsystematic literature review and expert opinion • Range of study designs • No grading system for recommendations • Recommendations: • Lifestyle modifications • Initial therapy for HTN • Compelling indications • Addressed secondary HTNand resistant HTN

  21. Recommendations for General Population Age ≥ 60 Years JNC 7 JNC8 BP Goal < 150/90 mmHg Rated Grade A Evidence for JNC8 • BP Goal < 140/90 mmHg (No age recommendations) • HYVET Trial • SHEP Trial • JATOS Trial • VALISH Trial

  22. Recommendations for General Population Age < 60 Years JNC 7 JNC8 SBP Goal < 140 mmHg Grade E DBP Goal < 90 mmHg Ages 30-59 years (Grade A) Ages 18-29 years (Grade E) Evidence for JNC8 • BP Goal < 140/90 mmHg • HDFP Trial • Hypertension-Stroke Cooperative Trial • MRC Trial • ANBP Trial • VA Cooperative Trial

  23. Recommendations for General Non-black Population (Including DM) JNC 7 JNC8 First-line Thiazide diuretics CCB ACE inhibitor ARB Grade B Evidence for JNC8 • First-line: Thiazide diuretics (no racial distinction made) • ALLHAT Trial • BP control more important than medication used • Alpha blockers not recommended first-line • LIFE Study • Beta-blockers not recommended first-line • Insufficient evidence to recommend other classes

  24. Recommendations for General Black Population (Including DM) JNC 7 JNC8 Initial treatment for black population (Grade B) with DM (Grade C) Thiazide diuretics CCB ALLHAT Trial • First-line: Thiazide diuretics (no racial distinction made) • Pre-specified subgroup analysis • Thiazide more effective in improving CV outcomes compared to ACEi in black patient subgroup • 51% higher rate of stroke (RR 1.51; 95% CI 1.22-1.86) with use of ACEi as initial therapy in black patients (compared to CCB) • 46% of patients in subgroup analysis had DM

  25. Recommendations for General Population Age ≥ 18 with CKD JNC 7 JNC8 Goal BP: < 140/90 mmHg Grade E Initial or add-on treatment: ACEi or ARB Grade B Regardless of race or DM status Evidence for JNC8 • Goal BP: < 130/80 mmHg • First-line agent: ACEi or ARB • AASK Trial • MDRD Trial • Potential benefit of goal <130/80 for patients with proteinuria (>3g/24 hours) • REIN-2 Trial • No trials showed goal <130/80 mmHg significantly lowered kidney or CV end points compared to 140/90

  26. Recommendations for General Population Age ≥ 18 with DM JNC 7 JNC8 Goal BP: < 140/90 mmHg Grade E Evidence for JNC8 • Goal BP: < 130/80 mmHg • ACCORD-BP Trial • No difference in outcomes with SBP < 140 vs. SBP < 120 • No good or fair quality trials to support DBP < 80

  27. Blood pressure goals in hypertensive patients SBP, systolic blood pressure; CV, cardiovascular; TIA, transient ischaemic attack; CHD, coronary heart disease; CKD, chronic kidney disease;DBP, diastolic blood pressure.

  28. Hypertension treatment for people with diabetes SBP, systolic blood pressure; DBP, diastolic blood pressure; RAS, renin–angiotensin system.

  29. Hypertension treatment for people with nephropathy SBP, systolic blood pressure; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; RAS, renin–angiotensin system.

  30. Lifestyle changes for hypertensive patients * Unless contraindicated. BMI, body mass index.

  31. ADA Guidelines for 2014 • Goal BP for patients with DM • Less than 140/80 mmHg • ACCORD-BP trial • HOT Trial • Showed 51% reduction in major CV events in patients with DM • Post-hoc analysis of small subgroup of the study (not pre-specified) • Evidence graded as low quality by JNC8 • Preferred Agents • ACEi or ARB • HOPE Study • Included non-hypertensive patients • Decreased risk of stroke with ACEi • Despite conflicting evidence, continue to recommend ACE/ARB first-line • Cite high CVD risk and high prevalence of undiagnosed CVD in patients with DM

  32. Thank You For Your Attention

More Related